


Nicotinamide N-oxide

Cat. No.:	HY-101407		
CAS No.:	1986-81-8		
Molecular Formula:	C ₆ H ₆ N ₂ O ₂		
Molecular Weight:	138.12		
Target:	CXCR; Drug Metabolite; Endogenous Metabolite		
Pathway:	GPCR/G Protein; Immunology/Inflammation; Metabolic Enzyme/Protease		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

H₂O : 20 mg/mL (144.80 mM; Need ultrasonic)
 DMSO : 10 mg/mL (72.40 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	7.2401 mL	36.2004 mL	72.4008 mL
	5 mM	1.4480 mL	7.2401 mL	14.4802 mL
	10 mM	0.7240 mL	3.6200 mL	7.2401 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
 Solubility: ≥ 1 mg/mL (7.24 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
 Solubility: ≥ 1 mg/mL (7.24 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Nicotinamide N-oxide, an in vivo nicotinamide metabolite, is a potent, and selective antagonist of the CXCR2 receptor.

IC₅₀ & Target

CXCR2 Human Endogenous Metabolite

In Vitro

Nicotinamide is one of the forms of vitamin B₃. It is a precursor for nicotinamide adenine dinucleotide, which is best known as an electron carrier in oxidative phosphorylation and as a cofactor for many dehydrogenases. It is metabolized through two enzymatic systems. The first system starts with the methylation of nicotinamide by nicotinamide N-methyltransferase, which can subsequently be oxidized by aldehyde oxidase. The second enzymatic system oxidizes nicotinamide to nicotinamide N-oxide^[1]. A series of nicotinamide N-oxides is synthesized and shown to be novel, potent, and selective

antagonists of the CXCR2 receptor. Compound 1 has demonstrated potent inhibition of neutrophil chemotaxis ($IC_{50}=10$ nM). Compound 2 is a selective antagonist of IL-8 binding ($IC_{50}=110$ nM) and potent inhibitor of neutrophil chemotaxis ($IC_{50}=170$ nM)^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Real AM, et al. Nicotinamide N-oxidation by CYP2E1 in human liver microsomes. *Drug Metab Dispos.* 2013 Mar;41(3):550-3.

[2]. Cutshall NS, et al. Nicotinamide N-oxides as CXCR2 antagonists. *Bioorg Med Chem Lett.* 2001 Jul 23;11(14):1951-4.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA